Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Phase II Reactions: Methylation Reactions

Phase II Reactions: Methylation Reactions

Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

Psychosis: Goals of Pharmacotherapy

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...

Psychological and Sociocultural Causes of Schizophrenia

Psychological and Sociocultural Causes of Schizophrenia

Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...

T Cell Types and Functions

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Gender-affirming care in South Africa: A cross-sectional survey of transgender and gender-diverse people in the Eastern and Western Cape provinces, South Africa.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2026

Same author

Parenteral artesunate compliance and hospital outcomes in children under five with suspected severe malaria in Sierra Leone.

Public health action·2026

Same author

SIGNIFIED: whole-body MRI screening in Li-Fraumeni syndrome in the UK.

ESMO open·2026

Same author

Extension of the intravitreal injection interval after switching to faricimab in patients with exudative AMD: The multicenter FAR WEST study.

Journal francais d'ophtalmologie·2026

Same author

Li Fraumeni syndrome in the UK: clinical characteristics and outcomes of TP53 carriers.

ESMO open·2025

Same author

Embedding systems thinking in local authority public health practice: a case study.

Perspectives in public health·2025

Search research articles

Related Experiment Video

Updated: Jun 8, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Relapse in psoriasis after methotrexate.

N A Karibasappa¹, A George

¹Department of Skin, STD and Leprology, J JM on Medical College, Davengere - 577 004, India, .

Indian Journal of Dermatology, Venereology and Leprology

|October 15, 2010

Summary

This summary is machine-generated.

Methotrexate (MTX) effectively treated chronic plaque psoriasis in 20 patients. However, relapses occurred within 6-12 weeks after stopping MTX or reducing the dose, indicating a need for long-term management strategies.

Related Experiment Videos

Last Updated: Jun 8, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Area of Science:

Dermatology
Immunology
Pharmacology

Background:

Chronic plaque psoriasis is an inflammatory skin condition often resistant to conventional treatments.
Methotrexate (MTX) is an established immunosuppressive agent used in treating various autoimmune diseases.

Purpose of the Study:

To evaluate the efficacy and safety of methotrexate in patients with chronic plaque psoriasis refractory to standard therapies.
To assess relapse rates after MTX discontinuation or dose reduction.

Main Methods:

Twenty patients with chronic plaque psoriasis received methotrexate at 15 mg/week for 4-12 weeks.
Laboratory investigations were performed before and after treatment.
Maintenance therapy and relapse patterns were monitored after treatment cessation.

Main Results:

Methotrexate treatment led to remission in patients with chronic plaque psoriasis.
All patients relapsed within 6-12 weeks after discontinuing MTX or reducing the dose to 5 mg/week for 8 weeks.
Pre- and post-treatment laboratory results remained within normal limits, with no significant side effects observed.

Conclusions:

Methotrexate demonstrates efficacy in managing chronic plaque psoriasis.
Discontinuation or dose reduction of MTX leads to rapid relapse, suggesting the need for sustained treatment protocols.
Methotrexate is a safe therapeutic option for this patient cohort.